Silverback Asset Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Silverback Asset Management’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-110,000	Closed	-$1.68M	–	59
2025 Q3	$1.68M	Sell	110,000 -20,000	-15%	-$260K	0.16%	57
2025 Q2	$1.15M	Buy	+130,000	New	+$1.14M	0.16%	55
2025 Q1	–	Hold	0	–	–	–	53
2024 Q3	–	Sell	-100,000	Closed	-$1.52M	–	82
2024 Q2	$1.41M	Buy	+100,000	New	+$1.63M	0.17%	72
2023 Q4	–	Sell	-100,000	Closed	-$1.17M	–	87
2023 Q3	$290K	Buy	+100,000	New	+$1.34M	0.04%	76

Other funds holding AVDL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GJL

Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Silverback Asset Management's AVDL Position: Q4 2025 in Review

Silverback Asset Management sold out of Avadel Pharmaceuticals (AVDL) in Q4 2025, closing a stake of 110,000 shares — an estimated $1.68M sold.

Silverback Asset Management first reported a position in AVDL in Q3 2023 and held it in 4 quarters. The position peaked at $1.68M in Q3 2025. 207 funds tracked by Wall St. Rank hold AVDL as of Q4 2025.

Silverback Asset Management reported no remaining Avadel Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Silverback Asset Management sold 110,000 Avadel Pharmaceuticals shares in Q4 2025, an estimated $1.68M.
Silverback Asset Management first reported a position in Avadel Pharmaceuticals in Q3 2023 and held it in 4 quarters.
Silverback Asset Management's Avadel Pharmaceuticals position peaked at $1.68M in Q3 2025.
207 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2025.

Based on Silverback Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.